Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group-Reference-Cited by-同舟云学术

Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Published:2017-02-17 Issue:12 Volume:123 Page:2368-2375
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Walterhouse David O.¹,Pappo Alberto S.²,Meza Jane L.³,Breneman John C.⁴,Hayes-Jordan Andrea⁵,Parham David M.⁶,Cripe Timothy P.⁷,Anderson James R.⁸,Meyer William H.⁹,Hawkins Douglas S.¹⁰

Affiliation:

1. Division of Hematology; Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine; Chicago Illinois

2. Division of Oncology, St. Jude Children's Research Hospital; Memphis Tennessee

3. Department of Biostatistics; University of Nebraska Medical Center College of Public Health; Omaha Nebraska

4. Division of Radiation Oncology, Cincinnati Children's Hospital Medical Center; Cincinnati Ohio

5. Division of Surgical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

6. Department of Pathology and Laboratory Medicine; Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California; Los Angeles California

7. Division of Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children's Hospital; Columbus Ohio

8. Oncology Clinical Research, Merck Research Laboratories; North Wales Pennsylvania

9. Jimmy Everest Section of Pediatric Hematology and Oncology; University of Oklahoma School of Medicine; Oklahoma City Oklahoma

10. Division of Hematology/Oncology; Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington; Seattle Washington

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference17 articles.

1. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: the Children's Oncology Group;Meza;J Clin Oncol,2006

2. The Third Intergroup Rhabdomyosarcoma Study;Crist;J Clin Oncol,1995

3. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease;Crist;J Clin Oncol,2001

4. Shorter duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group;Walterhouse;J Clin Oncol,2014

5. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group;Raney;J Clin Oncol,2011

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results of the JRS-I LRA0401 and LRB0402 Japan Rhabdomyosarcoma Study Group trials for low-risk embryonal rhabdomyosarcoma;International Journal of Clinical Oncology;2024-08-23

2. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group;The Lancet Oncology;2024-07

3. LRA0401/ LRB0402 protocols for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma based on the central pathological review system: The first report from the Japan Rhabdomyosarcoma Study Group;2024-01-12

4. Soft Tissue Sarcomas in Adolescents and Young Adults;Journal of Clinical Oncology;2023-11-15

5. Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies;Cancers;2023-11-02